Data thru May 13, 2026
HomeTrendsArticlesDrug MarketsTherapeutic ClassesManufacturersPricingContact
Back to Market Feed

DOXAZOSIN MESYLATE 2 MG TAB

Doxazosin mesylate
$0.0691per EA

Strength

2 mg/1

Manufacturer

Chartwell RX LLC

NDC

62135005290

Classification

Generic

Dosage Form

TABLET

Route

ORAL

Last Updated

4/22/2026

Active Ingredients

DOXAZOSIN MESYLATE

Approval Type

Generic (ANDA)

FDA Application

ANDA075646

On Market Since

10/18/2000

Pharmacological Classes

Adrenergic alpha-Antagonists
alpha-Adrenergic Blocker

Price History

1W

0.0%

1M

-0.4%

3M

-3.5%

6M

+1.2%

1Y

+13.2%

3Y

N/A

5Y

N/A

All

+15.5%

Generic Alternatives

No alternatives available

No alternatives found with the same active ingredient, strength, and dosage form.

Related Drugs

Same classification

CARVEDILOL 3.125 MG TABLET
Generic
00093005101•Teva Pharmaceuticals USA Inc.
$0.0172
per EA
CARVEDILOL 3.125 MG TABLET
Generic
00093005105•Teva Pharmaceuticals USA Inc.
$0.0172
per EA
CARVEDILOL 3.125 MG TABLET
Generic
00781522101•Sandoz Inc.
$0.0172
per EA
CARVEDILOL 3.125 MG TABLET
Generic
00904730561•Major Pharmaceuticals
$0.0172
per EA
CARVEDILOL 3.125 MG TABLET
Generic
65862014201•Aurobindo Pharma Limited
$0.0172
per EA
CARVEDILOL 3.125 MG TABLET
Generic
65862014205•Aurobindo Pharma Limited
$0.0172
per EA
CARVEDILOL 3.125 MG TABLET
Generic
68001015300•BluePoint Laboratories
$0.0172
per EA
CARVEDILOL 3.125 MG TABLET
Generic
68001015303•BluePoint Laboratories
$0.0172
per EA
CARVEDILOL 3.125 MG TABLET
Generic
68382009201•Zydus Pharmaceuticals (USA) Inc.
$0.0172
per EA
CARVEDILOL 3.125 MG TABLET
Generic
68382009205•Zydus Pharmaceuticals (USA) Inc.
$0.0172
per EA

Data Source

Pricing data sourced from the National Average Drug Acquisition Cost (NADAC) survey, published by the Centers for Medicare & Medicaid Services (CMS). Updated weekly.

Disclaimer

This site is for informational purposes only and does not constitute medical, pharmaceutical, or financial advice. NADAC prices are survey-based estimates and may not reflect actual acquisition costs at any specific pharmacy.

Navigate

HomeAboutManufacturersDrug MarketsTherapeutic ClassesTrendsArticlesPricingContact

© 2026 NADAC Intelligence. All rights reserved. Not affiliated with CMS or any government agency.

Terms of ServicePrivacy Policy